ArticlePloS one2017
Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- A framework policy analysis of single-dose HPV vaccination adoption in East Africa: a rapid review.BMC health services research · 2026Pooled it
- A systematic literature review of human papillomavirus vaccination strategies in delivery systems within national and regional immunization programs.Human vaccines & immunotherapeutics · 2024Pooled it
- Interventions aiming to improve menstrual, sexual, reproductive, and mental health among out-of-school girls: a systematic review.Frontiers in public health · 2024Pooled it
- Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review.BMC public health · 2023Pooled it
- Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: a systematic review.Health policy and planning · 2020Pooled it
- What works for human papillomavirus vaccine introduction in low and middle-income countries?Papillomavirus research (Amsterdam, Netherlands) · 2017Pooled it
- A Comparative Policy Analysis of HPV Vaccination Guidelines: Actors, Context, Content, and Process Across Eight Countries.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2026Article
- Article
- Review
- Review
- Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine.NPJ vaccines · 2025Article
- Article
- Introduction of the HPV Vaccine among Young Girls to Reduce the Long-Term Risk of Cervical Cancer in Eswatini: Programmatic Decision and Roll Out.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Review
- Understanding Kenyan policymakers' perspectives about the introduction of new maternal vaccines.Health policy and planning · 2025Article
- Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: an updated review.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Pathways and processes to adopting or switching to a single-dose HPV vaccination schedule in low- and middle-income countries: a qualitative study.PLOS global public health · 2025Article
- Public health concern-driven insights and response of low- and middle-income nations to the World health Organization call for cervical cancer risk eradication.Gynecologic oncology reports · 2024Article
- Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries.EClinicalMedicine · 2024Article
- Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo synthesise lessons learnt and determinants of success from human papillomavirus (HPV) vaccine demonstration projects and national programmes in low- and middle-income countries (LAMICs).
methodsInterviews were conducted with 56 key informants. A systematic literature review identified 2936 abstracts from five databases; after screening 61 full texts were included. Unpublished literature, including evaluation reports, was solicited from country representatives; 188 documents were received. A data extraction tool and interview topic guide outlining key areas of inquiry were informed by World Health Organization guidelines for new vaccine introduction. Results were synthesised thematically.
resultsData were analysed from 12 national programmes and 66 demonstration projects in 46 countries. Among demonstration projects, 30 were supported by the GARDASIL® Access Program, 20 by Gavi, four by PATH and 12 by other means. School-based vaccine delivery supplemented with health facility-based delivery for out-of-school girls attained high coverage. There were limited data on facility-only strategies and little evaluation of strategies to reach out-of-school girls. Early engagement of teachers as partners in social mobilisation, consent, vaccination day coordination, follow-up of non-completers and adverse events was considered invaluable. Micro-planning using school/ facility registers most effectively enumerated target populations; other estimates proved inaccurate, leading to vaccine under- or over-estimation. Refresher training on adverse events and safe injection procedures was usually necessary.
conclusionConsiderable experience in HPV vaccine delivery in LAMICs is available. Lessons are generally consistent across countries and dissemination of these could improve HPV vaccine introduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.